Altria Reports 2021 Second-Quarter and First-Half Results; Narrows 2021 Full-Year Earnings Guidance
Retrieved on:
Thursday, July 29, 2021
Key Points:
Infectious diseases
Adagio Therapeutics Appoints Leading Pharmaceutical and Regulatory Executives to its Board of Directors
Retrieved on:
Thursday, July 29, 2021
We are thrilled to welcome Mike to our board, who brings years of experience leading exceptional financial operations at both public and private companies within the pharmaceutical industry.
Key Points:
- We are thrilled to welcome Mike to our board, who brings years of experience leading exceptional financial operations at both public and private companies within the pharmaceutical industry.
- Tom Heyman has a long-standing track record in the biopharmaceutical industry, with particular experience in business development and venture capital.
- Adagio is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of antibody-based solutions for infectious diseases with pandemic potential.
- Adagio has secured manufacturing capacity for the production of ADG20 with third-party contract manufacturers through the completion of clinical trials and, if approved by regulatory authorities, through initial commercial launch.
Resilient Fruitvale Collaborative Submits $40M Emergency Fund Budget Request to Alameda County to Help Communities Hit Hard by the Pandemic
Retrieved on:
Thursday, July 29, 2021
Together, Resilient Fruitvale organizations have been on the frontlines and have served over 500,000 local residents since the beginning of the pandemic.
Key Points:
- Together, Resilient Fruitvale organizations have been on the frontlines and have served over 500,000 local residents since the beginning of the pandemic.
- The member organizations of the Resilient Fruitvale Collaborative have already provided a wide array of services that are unfunded by Alameda County.
- Resilient Fruitvale Collaborative Members emphasize the following:
Every organization that is part of the Resilient Fruitvale Collaborative has been on the frontlines supporting the communities most impacted by the pandemic. - For more information about the Resilient Fruitvale Collaborative, please visit the organizations website at: https://unitycouncil.org/who-we-are/resilient-fruitvale/
View source version on businesswire.com: https://www.businesswire.com/news/home/20210729005343/en/
Merck Announces Second-Quarter 2021 Financial Results
Retrieved on:
Thursday, July 29, 2021
Key Points:
Takeda and Frazier Healthcare Partners Announce Collaboration to Launch HilleVax, Inc. to Develop Clinical Stage Norovirus Vaccine Candidate
Retrieved on:
Thursday, July 29, 2021
Research, Medical Supplies, Infectious diseases, Clinical trials, Biotechnology, Health, Pharmaceutical, General Health, Science, Medical specialties, Clinical medicine, Health care, Norovirus, Vomiting, Takeda Pharmaceutical Company, Takeda, Gastroenteritis, Vaccine, Takeda Pharmaceutical Company Limited, Frazier Healthcare Partners, HilleVax, TAKEDA PHARMACEUTICAL COMPANY LIMITED, FRAZIER HEALTHCARE PARTNERS, HILLEVAX
Takeda Pharmaceutical Company Limited ( TSE:4502/NYSE:TAK ) (Takeda) and Frazier Healthcare Partners (Frazier) today announced a collaboration to launch HilleVax, Inc. (HilleVax), a biopharmaceutical company to develop and commercialize Takedas norovirus vaccine candidate.
Key Points:
- Takeda Pharmaceutical Company Limited ( TSE:4502/NYSE:TAK ) (Takeda) and Frazier Healthcare Partners (Frazier) today announced a collaboration to launch HilleVax, Inc. (HilleVax), a biopharmaceutical company to develop and commercialize Takedas norovirus vaccine candidate.
- Takeda will retain commercialization rights in Japan and HilleVax will integrate certain Japan development activities into its global development.
- Founded in 1991, Frazier Healthcare Partners is a leading provider of growth and venture capital to healthcare companies.
- Its initial program, HIL-214, is a virus-like particle (VLP) based vaccine candidate in development for the prevention of moderate-to-severe acute gastroenteritis caused by norovirus infection.
Arrowhead Pharmaceuticals Receives Breakthrough Therapy Designation from U.S. FDA for ARO-AAT for the Treatment of Alpha-1 Antitrypsin Deficiency Associated Liver Disease
Retrieved on:
Thursday, July 29, 2021
Infectious diseases, Automotive, General Automotive, FDA, Clinical trials, Cardiology, Biotechnology, Pharmaceutical, Health, Oncology, Health sciences, Life sciences, Health, Hepatology, Pharmacy, Food and Drug Administration, Pharmaceuticals policy, Breakthrough therapy, Alpha-1 antitrypsin deficiency, Fast track, Orphan drug, Alpha-1 Antitrypsin-Associated Liver Disease, Arrowhead Pharmaceuticals, ALPHA-1 ANTITRYPSIN-ASSOCIATED LIVER DISEASE, ARROWHEAD PHARMACEUTICALS
Investigational therapy ARO-AAT was also previously granted Orphan Drug designation and Fast Track designation from the FDA, and Orphan designation from the European Commission.
Key Points:
- Investigational therapy ARO-AAT was also previously granted Orphan Drug designation and Fast Track designation from the FDA, and Orphan designation from the European Commission.
- Javier San Martin, M.D., chief medical officer at Arrowhead, said: Patients with AATD associated liver disease currently have no available treatment options other than a liver transplant.
- Being granted Breakthrough Therapy designation from the FDA is an important milestone for the investigational ARO-AAT program.
- Individuals with the homozygous PiZZ genotype have severe deficiency of functional AAT leading to pulmonary disease and liver disease.
Enanta Pharmaceuticals to Host Conference Call on August 5 at 4:30 p.m. ET to Discuss its Financial Results for its Fiscal Third Quarter Ended June 30, 2021
Retrieved on:
Thursday, July 29, 2021
Enanta management will host a conference call at 4:30 p.m.
Key Points:
- Enanta management will host a conference call at 4:30 p.m.
- ET to discuss these results and provide an update on Enantas business, including its research and development pipeline.
- To participate in the live conference call, please dial 855-840-0595 in the U.S. or 518-444-4814 for international callers.
- ET on August 9, 2021 by dialing 855-859-2056 from the U.S. or 404-537-3406 for international callers.
Axcella Reports Second Quarter Financial Results and Provides Business Update
Retrieved on:
Thursday, July 29, 2021
Axcella (Nasdaq: AXLA), a clinical-stage biotechnology company pioneering a new approach to treat complex diseases and improve health using endogenous metabolic modulator (EMM) compositions, today announced financial results for the second quarter ended June 30, 2021 and provided a business update.
Key Points:
- Axcella (Nasdaq: AXLA), a clinical-stage biotechnology company pioneering a new approach to treat complex diseases and improve health using endogenous metabolic modulator (EMM) compositions, today announced financial results for the second quarter ended June 30, 2021 and provided a business update.
- As we enter the second half of 2021, maximizing clinical trial enrollment and expanding Axcellas pipeline are our primary areas of focus.
- Axcella continues to expect that its existing cash balance will be sufficient to meet the companys operating needs into the third quarter of 2022.
- ET to discuss the companys financial results and other recent business updates.
$1.3 Billion Worldwide Intracranial Pressure (ICP) Monitoring Devices Industry to 2027 - Impact of COVID-19 on the Market - ResearchAndMarkets.com
Retrieved on:
Thursday, July 29, 2021
The "Intracranial Pressure (ICP) Monitoring Devices - Global Market Trajectory & Analytics" report has been added to ResearchAndMarkets.com's offering.
Key Points:
- The "Intracranial Pressure (ICP) Monitoring Devices - Global Market Trajectory & Analytics" report has been added to ResearchAndMarkets.com's offering.
- Amid the COVID-19 crisis, the global market for Intracranial Pressure (ICP) Monitoring Devices estimated at US$1.3 Billion in the year 2020, is projected to reach a revised size of US$1.9 Billion by 2027, growing at a CAGR of 5.3% over the period 2020-2027.
- Invasive, one of the segments analyzed in the report, is projected to record 5.2% CAGR and reach US$1.7 Billion by the end of the analysis period.
- The U.S. Market is Estimated at $365 Million, While China is Forecast to Grow at 8.1% CAGR
The Intracranial Pressure (ICP) Monitoring Devices market in the U.S. is estimated at US$365 Million in the year 2020.
Icosavax Announces Pricing of Upsized Initial Public Offering
Retrieved on:
Thursday, July 29, 2021
Icosavax, Inc. (Nasdaq: ICVX), a biopharmaceutical company leveraging its innovative virus-like particle (VLP) platform technology to develop vaccines against infectious diseases, with an initial focus on life-threatening respiratory diseases, today announced the pricing of its upsized initial public offering of 12,133,333 shares of common stock at an initial public offering price of $15.00 per share.
Key Points:
- Icosavax, Inc. (Nasdaq: ICVX), a biopharmaceutical company leveraging its innovative virus-like particle (VLP) platform technology to develop vaccines against infectious diseases, with an initial focus on life-threatening respiratory diseases, today announced the pricing of its upsized initial public offering of 12,133,333 shares of common stock at an initial public offering price of $15.00 per share.
- The gross proceeds from the offering, before deducting underwriting discounts and commissions and other offering expenses payable by Icosavax, are expected to be approximately $182.0 million.
- In addition, Icosavax has granted the underwriters a 30-day option to purchase up to an additional 1,819,999 shares of common stock at the initial public offering price, less underwriting discounts and commissions.
- Icosavax is a biopharmaceutical company leveraging its innovative VLP platform technology to develop vaccines against infectious diseases, with an initial focus on life-threatening respiratory diseases.